Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...

It had been recognised as a second-line treatment for advanced HCC patients treated with sorafenib. In March 2025 ... "BMS’ Opdivo combo approved in US for hepatocellular carcinoma" was originally ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma ... therapy compared to lenvatinib or sorafenib. The combination therapy was generally well ...

The randomized, open-label CheckMate-9DW trial compared the combination of Opdivo plus Yervoy to investigator’s choice of lenvatinib or sorafenib ... Treatment for Unresectable or Metastatic ...

The "Sorafenib Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Sorafenib market report provides a comprehensive analysis of the market's characteristics, size, and growth, ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC).

as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The CheckMate-9DW combination of Opdivo plus Yervoy was previously granted accelerated approval ...